Document Classification

Section Type: RESULTS

Text: In the combination phase, adverse events that were reported at least 10 % more frequently with olaparib plus chemotherapy than with chemotherapy alone were alopecia (60 [74 %] of 81 vs 44 [59 %] of 75), nausea (56 [69 %] vs 43 [57 %]), neutropenia (40 [49 %] vs 29 [39 %]), diarrhoea (34 [42 %] vs 20 [27 %]), headache (27 [33 %] vs seven [9 %]), peripheral neuropathy (25 [31 %] vs 14 [19 %]), and dyspepsia (21 [26 %] vs 9 [12 %]) ; most were of mild-to-moderate intensity.